Notably, we observed favorable exarafenib sensitivity across multiple oncogenic RAS mutations (Fig. 2e and Supplementary Fig. 2d), suggesting the potential utility of using emerging pan-RAF inhibitors in a wider range of cancer types driven by these oncogenic RAS mutations. This evidence concerns the gene RAF1 and cancer.